Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage Trial

On August 19, 2026, Moderna, Inc. (NASDAQ: MRNA ) and Merck & Co., Inc. (NYSE: MRK ) said their personalized melanoma vaccine, intismeran, combined with Merck's Keytruda, met its goals in a Phase 3 trial of 1,137 patients. It reduced the risk of cancer recurrence and spread compared with Keytruda alone, Reuters reported.

It is the first positive late-stage trial result for an mRNA cancer vaccine. Merck's Jane Healy called the result a "clinically meaningful improvement," and said it was well tolerated, CNBC reported.

Both companies' shares rose on the news. Full data will be presented at an upcoming medical meeting alongside regulatory filing discussions. The companies are already running additional trials of the same vaccine-Keytruda combination in lung, bladder, kidney, pancreatic, and stomach cancers.

For Moderna, Inc. (NASDAQ:MRNA), this is proof that its mRNA platform works beyond vaccines for infectious disease. A positive Phase 3 readout validates years of personalized cancer vaccine development. It gives Moderna a genuine second growth pillar alongside its COVID business, one built on technology the company already knows how to manufacture and scale.

For Merck & Co., Inc. (NYSE:MRK), the result extends Keytruda's competitive life at a critical moment. Pairing Keytruda with a personalized vaccine gives Merck a differentiated, harder-to-copy combination therapy just as Keytruda itself approaches patent expiration later this decade. Hence, it protects franchise revenue through a next-generation product rather than the drug alone.

The pipeline behind this result is broad, not a single bet, since the firms are already running trials of the same vaccine-Keytruda combination in lung, bladder, kidney, pancreatic, and stomach cancers, Reuters reported. A platform technology that succeeds in melanoma and can be redirected at other tumor types by changing the targeted mutations offers multiple additional shots at approval rather than one binary outcome.

This is still one trial in one cancer type, not an approved product. Regulatory filings are only now beginning, which means approval, pricing, and reimbursement decisions remain ahead. each a point where the current enthusiasm could cool if later data or regulatory review raises new questions.

For Moderna, Inc. (NASDAQ:MRNA) specifically, the financial stakes are more concentrated than for Merck. Moderna is a smaller company whose commercial success still depends heavily on execution in oncology now that COVID vaccine demand has faded. So any delay or setback in this program carries more relative weight for Moderna's results than for a diversified pharmaceutical company the size of Merck & Co., Inc. (NYSE:MRK).